Test Menu

… PD-L1 28-8 FDA for NSCLC Alternative Name Formerly named PD-L1 28-8 FDA (OPDIVO® + YERVOY®) for NSCLC Methodology …

… PD-L1 SP142 FDA (TECENTRIQ®) for NSCLC Alternative Name PD-L1, SP142 Methodology Immunohistochemistry (IHC) Test …

… PD-L1 22C3 FDA (KEYTRUDA®) for Gastric/GEA Alternative Name PD-L1, 22C3 FDA (KEYTRUDA®) for Gastric/GEA Methodology …

… PD-L1 22C3 FDA (KEYTRUDA®) for HNSCC (Head & Neck) Alternative Name PD-L1, 22C3, KEYTRUDA Methodology Immunohistochemistry (IHC) …

… PD-L1 LDT Methodology Immunohistochemistry (IHC) Test Description Programmed cell death ligand 1 (PD-L1) is a transmembrane protein involved in cellular and …

… PD-L1 22C3 FDA (KEYTRUDA®) for TNBC (Breast) Methodology Immunohistochemistry (IHC) Test Description PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical …

… PD-L1 SP263 FDA for NSCLC Methodology Immunohistochemistry (IHC) Test Description The VENTANA PD-L1 (SP263) assay is a qualitative immunohistochemical assay …

… PD-L1 22C3 FDA for NSCLC Alternative Name Formerly named PD-L1 22C3 FDA (KEYTRUDA®) for NSCLC Methodology …

… PD-L1 22C3 FDA (KEYTRUDA®) for ESCC (Esophageal Squamous Cell … Methodology Immunohistochemistry (IHC) Test Description PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical …

… PD-L1 28-8 (OPDIVO®) for Gastric/GEJ/EAC Alternative Name PD-L1 28-8 (OPDIVO®) for Gastric/GEJ/Esophageal Adenocarcinoma …

… PD-L1 22C3 FDA (KEYTRUDA®) for Cervical Methodology Immunohistochemistry (IHC) Test Description PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical …

… methods: EGFR (PCR), ALK (FISH), ROS1 (FISH), and PD-L1 22C3 (IHC). EGFR alterations are detected using PCR … client services. Test may be ordered with an opt out of PD-L1 22C3 (IHC). Clinical Significance The Early-stage …

… Burden (TMB). FISH (1 biomarker): FGFR2 IHC (1 biomarker): PD-L1 LDT Clinical Significance The NeoTYPE Cholangiocarcinoma … (EGFR).  Other potential targets include IDH1/2 and PD-L1.jab Specimen Requirements FFPE tissue: Paraffin block …